Bone marrow-derived c-kit positive stem cell administration protects against diabetes-induced nephropathy in a rat model by reversing PI3K/AKT/GSK-3β pathway and inhibiting cell apoptosis

Arshad Ghaffari-Nasab,Fariba Ghiasi,Rana Keyhanmanesh,Leila Roshangar,Elnaz Salmani Korjan,Navid Nazarpoor,Fariba Mirzaei Bavil

DOI: https://doi.org/10.1007/s11010-023-04750-y

IF: 3.842

2023-05-03

Molecular and Cellular Biochemistry

Abstract:Stem cell-based therapy has been proposed as a novel therapeutic strategy for diabetic nephropathy. This study was designed to evaluate the effect of systemic administration of rat bone marrow-derived c-kit positive (c-kit + ) cells on diabetic nephropathy in male rats, focusing on PI3K/AKT/GSK-3 β pathway and apoptosis as a possible therapeutic mechanism. Twenty-eight animals were randomly classified into four groups: Control group (C), diabetic group (D), diabetic group, intravenously received 50 μl phosphate-buffered saline (PBS) containing 3 × 10 5 c-kit − cells (D + ckit − ); and diabetic group, intravenously received 50 μl PBS containing 3 × 10 5 c-Kit positive cells (D + ckit + ). Control and diabetic groups intravenously received 50 μl PBS. C-kit + cell therapy could reduce renal fibrosis, which was associated with attenuation of inflammation as indicated by decreased TNF- α and IL-6 levels in the kidney tissue. In addition, c-kit + cells restored the expression levels of PI3K, pAKT, and GSK-3 β proteins. Furthermore, renal apoptosis was decreased following c-kit + cell therapy, evidenced by the lower apoptotic index in parallel with the increased Bcl-2 and decreased Bax and Caspase-3 levels. Our results showed that in contrast to c-kit − cells, the administration of c-kit + cells ameliorate diabetic nephropathy and suggested that c-kit + cells could be an alternative cell source for attenuating diabetic nephropathy.

cell biology